The Tina’s Wish Boston and NextGen Boston Committees are dedicated to raising awareness and educating individuals about the signs, symptoms and risks of ovarian cancer in the Boston community. The Boston Committees host an annual spring reception to fulfill their mission.
For more information or to get involved with the Boston Committees for ovarian cancer awareness, please contact Anna Gibson at agibson@tinaswish.org or Janiya Wade at jwade@tinaswish.org.
See recap from the 2025 Boston Building Hope Event.
See all upcoming & past Boston Committee events.
Boston Committee
The Honorable Frank J. Bailey (ret.)
Pioneer Legal
Jack Bradley
Capstone Partners
Kristina Coccoluto
Kevin Courtney
(In memoriam)
Patrick Dinardo
Sullivan & Worcester
Julia Frost-Davies
Greenberg Traurig, Tina’s Wish Board Member
Andrew Gallo
Morgan, Lewis & Bockius
Tyler Harrington
Pathlight Capital
Joyce Kulhawik
Emmy Award-winning A&E Critic and 3x Cancer Survivor
Amy Kyle
Tina’s Wish Board Chair
Rebecca Matthews
Peter McGlynn
Bernkopf Goodman
Greg Milmoe
Greenberg Traurig
Laura Milmoe
Jim Nelson
AlixPartners
Patrick O’Toole
Kirkland & Ellis
Max Riffin
Prince Lobel Tye
Ms. Caitlin Roos
Bank of America Private Bank
Elle Simone Scott
(In memoriam)
Ed Smith
Morgan, Lewis & Bockius
Kitty Smith
Huy Tran
G2 Capital Advisors
Scott Vail
Akin Gump
Tina Vitale
UMB Bank
Sandra J. Vrejan
Morgan, Lewis & Bockius
Adrienne Walker
Foley & Lardner
Jim Wallack
Goulston & Storrs
Leslie Zmugg
Gordon Brothers
Boston NextGen Committee
Michelle Allison
Bank of America
Lucas Barrett
Choate, Hall & Stewart
Kate Bonavita
Morgan, Lewis & Bockius
Libby Canfield
Pathlight Capital
Bruna Carreiro
Lawson & Weitzen
Chris Carter
Morgan, Lewis & Bockius
Jessica Corr
Bank of America
Katherine Dobson Buckley
Morgan, Lewis & Bockius
Paige Edwards
Foley & Lardner
Brittany Fadous
Pathlight Capital
Emily Holt
Nixon Peabody
Peyton Jackson
Prescient Healthcare Group
Amy Kantor
Harvard T. H. Chan School of Public Health
Caroline Maxwell
Gordon Brothers
Morgan McCaskey
FTI Consulting
Ryan Rosenblatt
Sullivan & Worcester
Julia Schleppi
Carroll School
Harrison West
FTI Consulting
Lily Wetherington
Pathlight Capital
#1
deadliest gynecologic
cancer
27%
of women have a 5-year
survival rate after an
advanced stage diagnosis
61%
of women are diagnosed
at an advanced stage